Rare Endocrine Disorders
Explore facts and recommendations for pharmacological treatments for rare endocrine disorders.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
Mechanisms of Action of Long-Acting Growth Hormone Preparations in Children with Growth Hormone Deficiency (IME Content)
Whiteboard animation of various long-acting treatment options for pediatric growth hormone deficiency.
Sogroya® vs. Once-daily Growth Hormone - Phase 3 Pediatric Patients with Growth Hormone Deficiency (REAL 4)
Results of REAL 4, the pivotal Phase 3 trial investigating efficacy and safety of once-weekly Sogroya® compared to once daily Norditropin® in growth-hormone naïve pre-pubertal children with growth hormone deficiency.
Sogroya® vs. Once-daily Growth Hormone - Phase 2 Pediatric Patients with Growth Hormone Deficiency (REAL 3)
Overview of REAL 3, the Phase 2 dose-finding trial investigating efficacy and safety of once-weekly Sogroya® compared to once daily Norditropin® FlexPro® injection in growth-hormone naïve pre-pubertal children with growth hormone deficiency.
Sogroya® Treatment-naive Adults with Growth Hormone Deficiency (REAL 1)
Summary of REAL 1, the pivotal Phase 3 study evaluating the efficacy and safety of once-weekly Sogroya® compared to once-weekly placebo or once-daily Norditropin® in adults with growth hormone deficiency.
Albumin Interactions with Sogroya®
An overview of expected albumin interactions from hypoalbuminemia or other protein-bound drugs based on the mechanism of protraction (albumin-binding) used by Sogroya®
Growth Hormone Deficiency Practice Aids (IME Content)
Various practice aids for HCPs, including a chart detailing the patient experience / perspective, a 9-item shared decision-making questionnaire, and information and questionnaire pertaining to the LAuGH clinical trial / enrollment evaluation,
Growing Pains: Overcoming Challenges in the Management of Adult Growth Hormone Deficiency (IME content)
Overview of adult growth hormone deficiency, available and emerging treatment options, and healthcare transition challenges with long-term management
Continuing Education
Find accredited opportunities in rare endocrine education.
Sogroya® Mechanism of Action
This video discusses the mechanism of action of Sogroya®
Rare Endocrine Disorders
Rare Endocrine Disorders
Looking for additional resources?
Explore other libraries or search the Exchange.
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.